このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

NEXTURNBIOSCIENCE マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Young-Hwa Jung

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

NEXTURNBIOSCIENCE's (KOSDAQ:089140) Attractive Earnings Are Not All Good News For Shareholders

Mar 28

Shareholders Of NexturnLtd (KOSDAQ:089140) Must Be Happy With Their 119% Total Return

Jan 25

CEO（最高経営責任者

Young-Hwa Jung (65 yo)

no data

在職期間

Mr. Jung Young-Hwa serves as the Chief Executive Officer of NexturnBioscience Co., Ltd (formerly known as Nexturn Co.,Ltd.)

NEXTURNBIOSCIENCE マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

NEXTURNBIOSCIENCE's (KOSDAQ:089140) Attractive Earnings Are Not All Good News For Shareholders

Third quarter 2023 earnings released: EPS: ₩15.40 (vs ₩470 loss in 3Q 2022)

NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.

NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 5.9999959 billion in funding

NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 8.999999034 billion in funding from Flask Co., Ltd., GLK Equity Investment, SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.

NEXTURNBIOSCIENCE Co., Ltd. (KOSDAQ:A089140) agreed to acquire a 10.59% stake in Mirae Corporation (KOSE:A025560) from KANGLIM Co., Ltd (KOSDAQ:A014200).

First quarter 2023 earnings released: EPS: ₩37.00 (vs ₩48.00 loss in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: ₩138 loss per share (vs ₩138 loss in FY 2021)

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Less than half of directors are independent

NexturnBioscience Co., Ltd (KOSDAQ:A089140) acquired 8.83% stake in EV Advanced Material Co.,Ltd (KOSDAQ:A131400) from SL Vionics Co., Ltd. (KOSDAQ:A214310)

Studio Santa Claus Entertainment Co., Ltd. (KOSDAQ:A204630) acquired an additional 5.7% minority stake in NexturnBioscience Co., Ltd (KOSDAQ:A089140) from pacing, Sohn Young-sook, Peng Mi-sun and Shin Ji-yoon for KRW 9.8 billion.

Nexturn Bio Inc. Decides to Invest in the Development of A New Drug Pipeline for Diabetes Treatment Using Mirna

NexturnBioscience Co., Ltd announced that it has received KRW 13 billion in funding from Sangsangin Savings Bank, Investment Arm, Baro Savings Bank

NexturnBioscience Co., Ltd announced that it expects to receive KRW 13 billion in funding from Sangsangin Savings Bank, Investment Arm, Baro Savings Bank

New 90-day high: ₩17,550

New 90-day high: ₩13,900

Shareholders Of NexturnLtd (KOSDAQ:089140) Must Be Happy With Their 119% Total Return

New 90-day high: ₩13,700

New 90-day high: ₩12,100

New 90-day high: ₩10,000

New 90-day high: ₩8,780

New 90-day high - ₩8,610

New 90-day low - ₩7,140

CEO（最高経営責任者

在職期間

NEXTURNBIOSCIENCE マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

NEXTURNBIOSCIENCE's (KOSDAQ:089140) Attractive Earnings Are Not All Good News For Shareholders

Third quarter 2023 earnings released: EPS: ₩15.40 (vs ₩470 loss in 3Q 2022)

NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.

NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 5.9999959 billion in funding

NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 8.999999034 billion in funding from Flask Co., Ltd., GLK Equity Investment, SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.

NEXTURNBIOSCIENCE Co., Ltd. (KOSDAQ:A089140) agreed to acquire a 10.59% stake in Mirae Corporation (KOSE:A025560) from KANGLIM Co., Ltd (KOSDAQ:A014200).

First quarter 2023 earnings released: EPS: ₩37.00 (vs ₩48.00 loss in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: ₩138 loss per share (vs ₩138 loss in FY 2021)

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Less than half of directors are independent

NexturnBioscience Co., Ltd (KOSDAQ:A089140) acquired 8.83% stake in EV Advanced Material Co.,Ltd (KOSDAQ:A131400) from SL Vionics Co., Ltd. (KOSDAQ:A214310)

Studio Santa Claus Entertainment Co., Ltd. (KOSDAQ:A204630) acquired an additional 5.7% minority stake in NexturnBioscience Co., Ltd (KOSDAQ:A089140) from pacing, Sohn Young-sook, Peng Mi-sun and Shin Ji-yoon for KRW 9.8 billion.

Nexturn Bio Inc. Decides to Invest in the Development of A New Drug Pipeline for Diabetes Treatment Using Mirna

NexturnBioscience Co., Ltd announced that it has received KRW 13 billion in funding from Sangsangin Savings Bank, Investment Arm, Baro Savings Bank

NexturnBioscience Co., Ltd announced that it expects to receive KRW 13 billion in funding from Sangsangin Savings Bank, Investment Arm, Baro Savings Bank

New 90-day high: ₩17,550

New 90-day high: ₩13,900

Shareholders Of NexturnLtd (KOSDAQ:089140) Must Be Happy With Their 119% Total Return

New 90-day high: ₩13,700

New 90-day high: ₩12,100

New 90-day high: ₩10,000

New 90-day high: ₩8,780

New 90-day high - ₩8,610

New 90-day low - ₩7,140

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04